 | This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
Gulácsi László, [1] works as a Vice-Rector for Research, and a professor at Health Economics Research Centre, University Research and Innovation Center, Óbuda University of Budapest, Hungary. He is the funding head of the Innovation Management Doctoral School Óbuda University. [2] He is a member of the Standing Committee of Pharmacy, Hungarian Academy of Science.
By profession, he is a physician ( Debrecen Medical University), a specialist in public health, having university degrees of programming mathematics (Kossuth Lajos University of Arts and Sciences, Debrecen), mathematical economics and sociology ( Corvinus University of Budapest), and MSc in health economics ( York University). [3]
He holds PhD degrees from the following universities:
- Medical
University of Amsterdam
-
Corvinus University of Budapest (formerly Budapest University of Economics and Public Administration),
-
Semmelweis Medical University and,
-
Debrecen Medical University.
Habilitated in
University of Pécs in (2007) .
Doctor of the Hungarian Academy of Science(2017).
[4]
He worked as vice rector for research at Corvinus University of Budapest 2018–2019. He was a founding head of Department of Health Economics (2013–2020) and founding head of Health Economics and Health Technology Assessment Research Center, Corvinus University of Budapest (2002–2013). The Research Centre was founded in 1998 as the 'successor' to HunHTA (Hungarian Health Technology Assessment), the first HTA research institute in the Central Eastern European region. He is the founding past President of the Health and Health Care Economics Section of the Hungarian Economics Association (2010–2015).
He is a member of the editorial board of the European Journal of Health Economics (EJHE) IF:3.1, [5] the editorial board of the Hungarian Medical Journal IF: 0,540. [6]
Up to 2024, he was involved in 18 research projects funded by the European Commission (Framework Programmes, FP6, FP7, H2020), as a research leader, coordinator or participant.
2024-ben futó projektek:
- Development and evaluation of innovative and digital health technologies; Thematic Excellence Programme, Research Leader (National Research, Development and Innovation Fund project (TKP2021-NKTA-36). [7]
- Changes in the Socio-economic Burden of Epidermolysis Bullosa in Europe, BUR-EB;, [8] researcher (With the support of the European Joint Programme on Rare Diseases COFUND-EJP N825575, funded by the EU Horizon 2020 research and innovation programme, with the support of the National Research and Innovation Centre, 2019–2.1.7-ERA-NET).
To date, he has conducted and published nearly 40 Health Technology Assessments with colleagues, mostly in the field of immune-mediated diseases, with a special focus on drugs used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, spondylitis ankylopoetica, systemas sclerosis, scleroderma, sclerosis multiplex, psoriasis, Crohn's disease, ulcerative colitis. In addition, he has carried out health economics analyses in other important areas such as neurology (stroke, epilepsy, dementia, neuropathia, Parkinson disease), urology (benign prostatic hyperplasia, prostate cancer), cardiology (hypertonia, myocardial infarction, peripheral arterial disease), dermatology (psoriasis, hidradenitis suppurativa), diabetes, vascular surgery, hospital infection, attention deficit hyperactivity disorders, digital biomarkers, artificial intelligence in pediatric diabetes type 1. and implantable medical devices. His main achievements in the field of technology assessment are the analysis of biological agents and biosimilars. For the latter, he has been actively and successfully involved in health economics research on biosimilars and their uptake in European countries. Their research on biosimilars was published in 2014 in the European Journal of Health Economics Supplement, edited by guest editors. [9] The Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (European Medical Device Regulation-MDR) has been dealing with health technology assessment of medical devices since 2017. [10]
He has published a total of 775 scientific publications, 16 books, 78 book chapters and 64 other scientific works in the fields of health economics, technology assessment, public health and quality improvement. IF: 426,963 (first author: 124,423); MTMT Citation: 4938 (independent 3484), Hirsch index (MTMT) 36; [11] Google Scholar Citations 6688, Hirsch index: 49. [12] 49. Publication activity between 2018 and 2022 (5 years): D1=32; Q1=13; Q2=7; Q3=6; Q4=2; total: 60. Eddig 8 sikeres Ph.D. tézis témavezetője volt. Further details: https://hecon.uni-obuda.hu/en/home-english/
His research findings and health technology assessment reports have contributed to the development of biological disease-modifying antirheumatic drugs (DMARDs) therapies (infliximab, etanercept, tocilizumab, rituximab, abatacept) have become publicly funded in Hungary and patients with rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis and psoriasis have access to appropriate therapy. László Gulácsi founded the first Health Technology Assessment Research Centre (HunHTA) at Corvinus University in 2000, which has carried out nearly 40 technology analyses in different specialties (rheumatology, gastroenterology, neurology, urology, orthopaedics, internal medicine, cardiology).
His research has contributed substantially to the rapid introduction of biosimilar of disease-modifying antirheumatic drugs (biological DMARDs) into practice and received public funding across Europe. The most important publications on biologics and biosimilars in the field of immune-mediated disease indications. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] László Gulácsi was one of the first to draw attention to the fact that in the case of biological therapies, it is not individual biological agents but therapeutic sequences that should be compared in the context of health economics analyses. His research has pointed out that the availability of effective innovative biological therapies varies considerably between European countries and that this difference cannot be fully explained by differences in GDP between countries. [29] [30] He was among the first to demonstrate that the efficacy and safety of bilogic and biosimilar agents are not significantly different. He is among the first to demonstrate that the quality of life of patients receiving a biologic/biosimilar therapy is not significantly different from that of the general population. He was the first to show that dysmenorrhoea is the most important factor reducing quality of life in young women. [31]
- ^ "Gulácsi László - ODT Személyi adatlap". doktori.hu.
- ^ "Innováció Menedzsment Doktori Iskola".
- ^ "University of York".
- ^ "A krónikus immunológiai betegségek egészségügyi közgazdaságtani és technológiaelemzési vizsgálata".
- ^ "The European Journal of Health Economics". SpringerLink.
- ^ "Orvosi Hetilap". AKJournals.
- ^ "Innovatív és digitális egészségipari technológiák (TKP 2021-2025)". July 1, 2024.
- ^ "BUR-EB".
- ^ "The European Journal of Health Economics | Volume 15, supplement issue 1". SpringerLink.
- ^ "MDR" (PDF).
- ^ "Magyar Tudományos Művek Tára". m2.mtmt.hu.
- ^ "Prof. László Gulácsi, DSc". scholar.google.com.
- ^ "Biosimilars for the management of rheumatoid arthritis: economic considerations".
- ^ "Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists".
- ^ "A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia".
- ^ "Use of biologics for psoriasis in Central and Eastern European countries".
- ^ "Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe]".
- ^ "The changing landscape of biosimilars in rheumatology".
- ^ "Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences".
- ^ "Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists".
- ^ "Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe".
- ^ "Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe".
- ^ "Economic evaluations of interventions to prevent healthcare-associated infections – literature review".
- ^ "Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations".
- ^ "The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries".
- ^ "EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis".
- ^ "Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis".
- ^ "Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis".
- ^ "The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries".
- ^ "Access to biologicals in Crohn's disease in ten European countries" (PDF).
- ^ "Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods".
| This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
Gulácsi László, [1] works as a Vice-Rector for Research, and a professor at Health Economics Research Centre, University Research and Innovation Center, Óbuda University of Budapest, Hungary. He is the funding head of the Innovation Management Doctoral School Óbuda University. [2] He is a member of the Standing Committee of Pharmacy, Hungarian Academy of Science.
By profession, he is a physician ( Debrecen Medical University), a specialist in public health, having university degrees of programming mathematics (Kossuth Lajos University of Arts and Sciences, Debrecen), mathematical economics and sociology ( Corvinus University of Budapest), and MSc in health economics ( York University). [3]
He holds PhD degrees from the following universities:
- Medical
University of Amsterdam
-
Corvinus University of Budapest (formerly Budapest University of Economics and Public Administration),
-
Semmelweis Medical University and,
-
Debrecen Medical University.
Habilitated in
University of Pécs in (2007) .
Doctor of the Hungarian Academy of Science(2017).
[4]
He worked as vice rector for research at Corvinus University of Budapest 2018–2019. He was a founding head of Department of Health Economics (2013–2020) and founding head of Health Economics and Health Technology Assessment Research Center, Corvinus University of Budapest (2002–2013). The Research Centre was founded in 1998 as the 'successor' to HunHTA (Hungarian Health Technology Assessment), the first HTA research institute in the Central Eastern European region. He is the founding past President of the Health and Health Care Economics Section of the Hungarian Economics Association (2010–2015).
He is a member of the editorial board of the European Journal of Health Economics (EJHE) IF:3.1, [5] the editorial board of the Hungarian Medical Journal IF: 0,540. [6]
Up to 2024, he was involved in 18 research projects funded by the European Commission (Framework Programmes, FP6, FP7, H2020), as a research leader, coordinator or participant.
2024-ben futó projektek:
- Development and evaluation of innovative and digital health technologies; Thematic Excellence Programme, Research Leader (National Research, Development and Innovation Fund project (TKP2021-NKTA-36). [7]
- Changes in the Socio-economic Burden of Epidermolysis Bullosa in Europe, BUR-EB;, [8] researcher (With the support of the European Joint Programme on Rare Diseases COFUND-EJP N825575, funded by the EU Horizon 2020 research and innovation programme, with the support of the National Research and Innovation Centre, 2019–2.1.7-ERA-NET).
To date, he has conducted and published nearly 40 Health Technology Assessments with colleagues, mostly in the field of immune-mediated diseases, with a special focus on drugs used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, spondylitis ankylopoetica, systemas sclerosis, scleroderma, sclerosis multiplex, psoriasis, Crohn's disease, ulcerative colitis. In addition, he has carried out health economics analyses in other important areas such as neurology (stroke, epilepsy, dementia, neuropathia, Parkinson disease), urology (benign prostatic hyperplasia, prostate cancer), cardiology (hypertonia, myocardial infarction, peripheral arterial disease), dermatology (psoriasis, hidradenitis suppurativa), diabetes, vascular surgery, hospital infection, attention deficit hyperactivity disorders, digital biomarkers, artificial intelligence in pediatric diabetes type 1. and implantable medical devices. His main achievements in the field of technology assessment are the analysis of biological agents and biosimilars. For the latter, he has been actively and successfully involved in health economics research on biosimilars and their uptake in European countries. Their research on biosimilars was published in 2014 in the European Journal of Health Economics Supplement, edited by guest editors. [9] The Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices (European Medical Device Regulation-MDR) has been dealing with health technology assessment of medical devices since 2017. [10]
He has published a total of 775 scientific publications, 16 books, 78 book chapters and 64 other scientific works in the fields of health economics, technology assessment, public health and quality improvement. IF: 426,963 (first author: 124,423); MTMT Citation: 4938 (independent 3484), Hirsch index (MTMT) 36; [11] Google Scholar Citations 6688, Hirsch index: 49. [12] 49. Publication activity between 2018 and 2022 (5 years): D1=32; Q1=13; Q2=7; Q3=6; Q4=2; total: 60. Eddig 8 sikeres Ph.D. tézis témavezetője volt. Further details: https://hecon.uni-obuda.hu/en/home-english/
His research findings and health technology assessment reports have contributed to the development of biological disease-modifying antirheumatic drugs (DMARDs) therapies (infliximab, etanercept, tocilizumab, rituximab, abatacept) have become publicly funded in Hungary and patients with rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis and psoriasis have access to appropriate therapy. László Gulácsi founded the first Health Technology Assessment Research Centre (HunHTA) at Corvinus University in 2000, which has carried out nearly 40 technology analyses in different specialties (rheumatology, gastroenterology, neurology, urology, orthopaedics, internal medicine, cardiology).
His research has contributed substantially to the rapid introduction of biosimilar of disease-modifying antirheumatic drugs (biological DMARDs) into practice and received public funding across Europe. The most important publications on biologics and biosimilars in the field of immune-mediated disease indications. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] László Gulácsi was one of the first to draw attention to the fact that in the case of biological therapies, it is not individual biological agents but therapeutic sequences that should be compared in the context of health economics analyses. His research has pointed out that the availability of effective innovative biological therapies varies considerably between European countries and that this difference cannot be fully explained by differences in GDP between countries. [29] [30] He was among the first to demonstrate that the efficacy and safety of bilogic and biosimilar agents are not significantly different. He is among the first to demonstrate that the quality of life of patients receiving a biologic/biosimilar therapy is not significantly different from that of the general population. He was the first to show that dysmenorrhoea is the most important factor reducing quality of life in young women. [31]
- ^ "Gulácsi László - ODT Személyi adatlap". doktori.hu.
- ^ "Innováció Menedzsment Doktori Iskola".
- ^ "University of York".
- ^ "A krónikus immunológiai betegségek egészségügyi közgazdaságtani és technológiaelemzési vizsgálata".
- ^ "The European Journal of Health Economics". SpringerLink.
- ^ "Orvosi Hetilap". AKJournals.
- ^ "Innovatív és digitális egészségipari technológiák (TKP 2021-2025)". July 1, 2024.
- ^ "BUR-EB".
- ^ "The European Journal of Health Economics | Volume 15, supplement issue 1". SpringerLink.
- ^ "MDR" (PDF).
- ^ "Magyar Tudományos Művek Tára". m2.mtmt.hu.
- ^ "Prof. László Gulácsi, DSc". scholar.google.com.
- ^ "Biosimilars for the management of rheumatoid arthritis: economic considerations".
- ^ "Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists".
- ^ "A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia".
- ^ "Use of biologics for psoriasis in Central and Eastern European countries".
- ^ "Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe]".
- ^ "The changing landscape of biosimilars in rheumatology".
- ^ "Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences".
- ^ "Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists".
- ^ "Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe".
- ^ "Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe".
- ^ "Economic evaluations of interventions to prevent healthcare-associated infections – literature review".
- ^ "Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations".
- ^ "The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries".
- ^ "EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis".
- ^ "Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis".
- ^ "Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis".
- ^ "The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries".
- ^ "Access to biologicals in Crohn's disease in ten European countries" (PDF).
- ^ "Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods".